Autopsy report · NCT04102124
A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC
Cause of deathFunding or business
“The sponsor's R\&D strategy is adjusted.”
Life of this trial
- Registered 5 months after it had already started.
- Ran for about 2 years 5 months before it stopped.
- 20 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Sponsor type
- Industry
- Conditions
- Prostate Cancer; Castration-resistant Prostate Cancer
- Interventions
- SHR3680; SHR3162; SHR3680(Placebo); SHR3162(Placebo)
- Participants
- 20
- Sites
- 1
- Countries
- China
Trials that died the same way
- A Study to Assess the Efficacy and Safety of HRG2005 Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
“Sponsor's R\&D strategy adjusted.” - A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma
“The sponsor has adjusted its R\&D strategy.” - A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
“Sponsor R \& D Strategy Adjustment” - Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.
“The Sponsor changed R\&D strategy and priority.” - Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
“sponsor strategy change”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.